NETRIS Pharma
  • Our company
    • About us
    • Our team
    • Scientific Advisory Board
    • Clinical Advisors
  • Our Science
    • Concept and Focus on oncology
    • Therapeutic strategy
  • Portfolio
    • Pipeline
    • Netrin-1 Lead Program
  • Publications
  • News
  • Contact us
  • Our company
    • About us
    • Our team
    • Scientific Advisory Board
    • Clinical Advisors
  • Our Science
    • Concept and Focus on oncology
    • Therapeutic strategy
  • Portfolio
    • Pipeline
    • Netrin-1 Lead Program
  • Publications
  • News
  • Contact us

Discover our news

31 décembre 2020
9

NETRIS Pharma Announces First Patient Dosed in Phase Ib/II

By Netris Pharma | Actualités, News

NETRIS Pharma Announces First Patient Dosed in Phase Ib/II GYNet Study of First-in-Class NP137 in combination with chemotherapy and/or KEYTRUDA®   December 31, 2020 LYON, France – NETRIS Pharma, a…

Read More
26 décembre 2020
8

Bio Partnering @ JPM – January 2021

By Netris Pharma | Actualités, News

NETRIS Pharma will attend the Bio Partnering  @ JPM conference that will take place Virtual  (Jan 11th-15th, 2021). Our team members will be pleased to meet with you and discuss…

Read More
23 décembre 2020
9

NETRIS Pharma successfully completes a €16.1m Series A

By Netris Pharma | Actualités, News

December 23rd, 2020 – Geneva – Switzerland and Lyon – France NETRIS Pharma, a clinical-stage biopharmaceutical company developing next generation molecules targeting cancer, today announced the closing of a €16.1m…

Read More
5 mai 2020
8

Press release – Clinical Trial Collaboration Agreement with MSD (Merck US)

By Netris Pharma | Actualités, News

NETRIS Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate NP137 in Combination with KEYTRUDA® (Pembrolizumab) in Advanced Uterine and Cervical Tumors Unique NP137 mechanism targeting netrin-1 could alleviate…

Read More
28 avril 2020
0

NETRIS Pharma welcomes its new CMO

By Netris Pharma | Actualités, Event
NETRIS Pharma is pleased to announce the arrival of Frédéric Le Bras, MD; as the new company Chief Medical Officer. Graduated from René Descartes University in Paris, Frédéric obtained his...
Read More
1 octobre 2019
1

BIO-Europe – Hamburg , 2019

By Netris Pharma | Actualités, Event
NETRIS Pharma will attend the 2019 Bio-Europe conference in Hamburg, Germany  (November 11th-13th). Our team members will be pleased to meet with you and discuss Business Development and investment opportunities. Please...
Read More
24 septembre 2019
0

ESMO Congress – Barcelona, 2019

By Netris Pharma | Actualités, Event
Dr Philippe Cassier, Principal Investigator of NETRIS Pharma Phase 1 dose-escalation clinical trial on solid tumors, will present the results of the trial at ESMO Conference in Barcelona. The presentation...
Read More
28 juin 2019
0

ANR granted the RHU DEPGYN project

By Netris Pharma | Actualités, News

NETRIS Pharma is pleased to announce that the ANR (Agence Nationale de la Recherche) allocated a 6.6 M€ grant to the RHU DEPGYN project aiming to develop new therapeutic approaches…

Read More
29 mars 2019
0

Colloque Cancers de la Femme – Paris, 2019

By Netris Pharma | Actualités, Event

NETRIS Pharma will attend the Colloque on Women Cancer in Paris (March 30th, 2019). In partnership with “La Ligue contre le Cancer” Association, the following theme will be discussed by…

Read More
3 janvier 2019
0

Annual J.P. Morgan Healthcare Conference – San Francisco, 2019

By Netris Pharma | Actualités, Event

NETRIS Pharma will attend the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California (January 07th-10th, 2019). Our team members attending the event will be pleased to meet you for…

Read More
12 décembre 2018
2

Press release – Completion of NP137 Dose-Escalation Phase 1 trial

By Netris Pharma | Actualités

NETRIS Pharma successfully completes first clinical study with first-in-class netrin-1 inhibitor NP137 in patients with advanced solid tumors Dose-escalation part of study met primary objective Study shows NP137 to have…

Read More
14 mai 2018
0

BIO International Convention – Boston, 2018

By Netris Pharma | Actualités

NETRIS Pharma will attend the 2018 BIO International Convention event in Boston, MA (June 04th-07th). Our team members attending the event will be pleased to meet you for discussing opportunities…

Read More
13 avril 2018
0

Presentation at PEGS – Boston, 2018

By Netris Pharma | Actualités, Event

NETRIS Pharma will attend PEGS 2018 event in Boston, MA (April 30th-May 04th). Our CEO, Pr. Patrick Mehlen, will give a presentation on April 30th within the Oncology stream – Antibodies…

Read More
19 février 2018
0

BIO-Europe Spring – Amsterdam, 2018

By Netris Pharma | Actualités, Event

NETRIS Pharma will attend the BIO-Europe Spring 2018 event in Amsterdam, Netherlands (March 12th-14th). Our team members attending the event will be pleased to meet you for discussing opportunities with…

Read More
9 janvier 2018
0

Pr. Bernet appointed as Knight of the Legion of Honor

By Netris Pharma | Actualités, News

The President of the French Republic appointed Pr. Agnès Bernet, co-founder and CSO of NETRIS Pharma, to the highest French distinction as Knight of the Legion of Honor. The award…

Read More
5 janvier 2018
0

Annual J.P. Morgan Healthcare Conference – San Francisco, 2018

By Netris Pharma | Actualités, Event

NETRIS Pharma will attend the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, California (January 08th-11th, 2018). Our team members attending the event will be pleased to meet you…

Read More
21 mars 2017
0

Press release – Start of NP137 Phase I clinical trial

By | Actualités

Lyon, France – 21 March 2017 – NETRIS Pharma Starts Enrollment of First Clinical Study to Evaluate Drug Candidate Targeting Dependence Receptors. NETRIS Pharma, a pioneer in the development of dependence…

Read More

Contact

NETRIS PHARMA
Centre Léon Bérard
28 rue Laennec
69008 LYON
France
+33 (0)4 78 78 29 53
contact@netrispharma.com

Links

  • Mentions légales
  • Careers

News

  • NETRIS Pharma Announces First Patient Dosed in Phase Ib/II 31 décembre 2020
  • Bio Partnering @ JPM – January 2021 26 décembre 2020
  • NETRIS Pharma successfully completes a €16.1m Series A 23 décembre 2020
  • Press release – Clinical Trial Collaboration Agreement with MSD (Merck US) 5 mai 2020

Copyright © 2016 NETRIS Pharma | Sitemap page

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.OK